Carderock Capital Management Inc. Has $7.81 Million Holdings in Eli Lilly and Company $LLY

Key Points

• Carderock Capital Management Inc. increased its holdings in Eli Lilly and Company by 16.5% during the first quarter, owning 9,460 shares worth approximately $7.81 million.
• Analysts have varying ratings for Eli Lilly, with one upgrade from buy to strong-buy and recent downgrades that reflect mixed sentiments about the stock's performance.
• Eli Lilly reported strong earnings of $6.31 per share, exceeding expectations, with revenues reaching $15.56 billion, a 37.6% increase year-over-year.

Carderock Capital Management Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,460 shares of the company's stock after buying an additional 1,337 shares during the period. Eli Lilly and Company makes up 2.1% of Carderock Capital Management Inc.'s investment portfolio, making the stock its 24th largest holding. Carderock Capital Management Inc.'s holdings in Eli Lilly and Company were worth $7,813,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LLY. Duquesne Family Office LLC grew its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the period. Corient IA LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $570,000. LS Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP bought a new stake in Eli Lilly and Company in the 1st quarter valued at about $14,866,000. Finally, Prism Advisors Inc. acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $207,000. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on LLY shares. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $754.24 on Thursday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $713.86 billion, a price-to-earnings ratio of 49.30, a PEG ratio of 1.04 and a beta of 0.47. The stock has a 50 day moving average of $742.00 and a 200 day moving average of $779.25. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.